Latest Healthcare Software News

PainChek Ltd has secured FDA De Novo clearance for its Adult App, marking a pivotal entry into the US long-term care market and setting the stage for global expansion including its Infant App.

PainChek has secured FDA De Novo clearance for its Adult App, opening immediate access to a $175 million AUD US long-term care market and advancing its Infant App commercialization targeting a $15 billion AUD global opportunity.

PainChek Limited has achieved a landmark FDA De Novo classification for its PainChek Adult App, positioning it as the first regulated medical device for pain assessment in the US aged care sector and opening a $100 million annual market opportunity.

Singular Health Group reported a $6.38 million loss for FY2025 while securing a pivotal $1.3 million commercial agreement with US-based Provider Network Solutions to deploy its 3DICOM software. The company also completed a major cloud migration of its platform, positioning itself for growth in the US healthcare market.

Visionflex Group Limited’s FY25 results highlight a strong transition to a SaaS-driven model, with recurring revenue surging 49% to $1.9 million and total revenue up 33%. Key government and private sector contracts underpin future growth prospects.

333D Limited has reported a remarkable turnaround for the year ended June 2025, posting a profit after tax of $143,777 on the back of a 426% revenue increase driven by its digital asset management strategy. The company also adopted a Bitcoin Treasury Management Policy, signaling a new phase in its financial approach.

Alcidion Group Limited has delivered a record FY25 with $40.8 million in revenue and underlying EBITDA of $5.1 million, driven by a landmark $39 million UK electronic patient record contract and strong recurring revenue growth.

Global Health Limited reported a reduced net loss for FY2025, driven by growing subscription revenue and strategic AI integration as it transitions to a SaaS platform.

PainChek Ltd reports robust growth with 100,000 contracted licences globally and positive FDA clearance progress, alongside a promising launch of its Infant App targeting a vast new market.